April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 14, 2025

Early RNAi Therapeutic Treatment May Improve Survival in hATTR-PN

"In a disease characterized by unrelenting decline, the results depict the long-term clinical stability afforded by TTR reduction and the long-term safety of patisiran treatment."

Conexiant

April 09, 2025

Buprenorphine Data Reveal Prescribing Pivot

The rise in extended-release buprenorphine patients signals increasing access and a willingness to adopt this treatment option, researchers noted.

Conexiant

April 09, 2025

Oral Microbiome Linked to Chronic Pain in Women

Study finds poor oral health and oral pathobionts associated with pain in migraine, fibromyalgia, and abdominal disorders, suggesting possible treatment avenues.

Conexiant

April 07, 2025

Cannabis for Pain: ACP Issues Best Practices

New guidelines from the American College of Physicians address the limited benefits and potential harms of cannabis and cannabinoids for chronic noncancer pain management.

Conexiant

April 02, 2025

Ultraprocessed Foods Linked to Arthritis Risk

"Each 10-percentage point higher %TEI from UPFs was associated with a 4% higher likelihood of having any type of arthritis," researchers noted.

Conexiant

April 02, 2025

Do NSAIDs Prevent Dementia?

Long-term anti-inflammatory use linked to 12% reduced dementia risk in 14-year population study.

Conexiant

April 01, 2025

Could Brain Imaging Plus VR Minimize Cancer-Related Pain?

Researchers assessed the efficacy of combining brain imaging with functional near-infrared spectroscopy—a strategy designed to gauge the severity of pain using a head cap fitted with optical sensors—a...

The ASCO Post

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant